# Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: <scp>HARMONY</scp> 5

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/efficacy-and-tolerability-of-albiglutide-versus-placebo-or-pioglitazone-over-1/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Philip Home,Paramesh Shamanna,Murray Stewart,Fang Yang,Michael Miller,Caroline Perry,Molly C. Carr |
| Citations | 98 |
| DOI | 10.1111/dom.12414 |
| Fields | Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W2023695436 |
| PMID | 25406730 |
| Type | article |
| Year | 2014 |

## Paper authors

- [Molly C. Carr](https://scholariq.org/researchers/molly-c-carr/)

## Paper journal

- [Diabetes Obesity and Metabolism](https://scholariq.org/journals/diabetes-obesity-and-metabolism/)

## Paper primary topic

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)

## Paper topics

- [Diabetes Treatment and Management](https://scholariq.org/topics/diabetes-treatment-and-management/)
- [Diabetes Management and Research](https://scholariq.org/topics/diabetes-management-and-research/)
- [Pancreatic function and diabetes](https://scholariq.org/topics/pancreatic-function-and-diabetes/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.